{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Glioblastoma", "query": { "condition": "Refractory Glioblastoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 95, "total_pages": 10, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Glioblastoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T07:47:03.315Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01386710", "title": "Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma Multiforme", "Anaplastic Astrocytoma" ], "interventions": [ { "name": "Bevacizumab and Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2011-09", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2025-04-09", "last_synced_at": "2026-05-22T07:47:03.315Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01386710" }, { "nct_id": "NCT04051606", "title": "Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Glioblastoma" ], "interventions": [ { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2019-07-31", "completion_date": "2024-03-20", "has_results": false, "last_update_posted_date": "2025-06-05", "last_synced_at": "2026-05-22T07:47:03.315Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04051606" }, { "nct_id": "NCT00003876", "title": "Internal Radiation Therapy Plus Carmustine Implants in Treating Patients With Recurrent or Refractory Malignant Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "polifeprosan 20 with carmustine implant", "type": "DRUG" }, { "name": "surgical procedure", "type": "PROCEDURE" }, { "name": "iodine I 125", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Barrett Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-04", "completion_date": "2004-05", "has_results": false, "last_update_posted_date": "2013-06-26", "last_synced_at": "2026-05-22T07:47:03.315Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003876" }, { "nct_id": "NCT02743078", "title": "Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "Glioma", "Gliosarcoma" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "TTFields Therapy", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "RTOG Foundation, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 3, "start_date": "2017-05-09", "completion_date": "2019-10-15", "has_results": true, "last_update_posted_date": "2021-06-02", "last_synced_at": "2026-05-22T07:47:03.315Z", "location_count": 11, "location_summary": "La Jolla, California • Orange, California • Miami, Florida + 8 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02743078" }, { "nct_id": "NCT02255461", "title": "Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Choroid Plexus Tumor", "Childhood Ependymoblastoma", "Childhood Grade III Meningioma", "Childhood High-grade Cerebellar Astrocytoma", "Childhood High-grade Cerebral Astrocytoma", "Childhood Medulloepithelioma", "Recurrent Childhood Anaplastic Astrocytoma", "Recurrent Childhood Anaplastic Oligoastrocytoma", "Recurrent Childhood Anaplastic Oligodendroglioma", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Giant Cell Glioblastoma", "Recurrent Childhood Glioblastoma", "Recurrent Childhood Gliomatosis Cerebri", "Recurrent Childhood Gliosarcoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Pineoblastoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor" ], "interventions": [ { "name": "palbociclib isethionate", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Pediatric Brain Tumor Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "4 Years to 21 Years" }, "enrollment_count": 35, "start_date": "2014-12-08", "completion_date": "2019-02-25", "has_results": true, "last_update_posted_date": "2021-03-02", "last_synced_at": "2026-05-22T07:47:03.315Z", "location_count": 11, "location_summary": "Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02255461" }, { "nct_id": "NCT01076530", "title": "Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Atypical Teratoid/Rhabdoid Tumor", "Childhood Central Nervous System Choriocarcinoma", "Childhood Central Nervous System Embryonal Tumor", "Childhood Central Nervous System Germinoma", "Childhood Central Nervous System Mixed Germ Cell Tumor", "Childhood Central Nervous System Teratoma", "Childhood Central Nervous System Yolk Sac Tumor", "Childhood Choroid Plexus Tumor", "Childhood Craniopharyngioma", "Childhood Ependymoblastoma", "Childhood Grade I Meningioma", "Childhood Grade II Meningioma", "Childhood Grade III Meningioma", "Childhood High-grade Cerebellar Astrocytoma", "Childhood High-grade Cerebral Astrocytoma", "Childhood Infratentorial Ependymoma", "Childhood Low-grade Cerebellar Astrocytoma", "Childhood Low-grade Cerebral Astrocytoma", "Childhood Medulloepithelioma", "Childhood Mixed Glioma", "Childhood Oligodendroglioma", "Childhood Supratentorial Ependymoma", "Extra-adrenal Paraganglioma", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Central Nervous System Embryonal Tumor", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Pineoblastoma", "Recurrent Childhood Spinal Cord Neoplasm", "Recurrent Childhood Subependymal Giant Cell Astrocytoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway and Hypothalamic Glioma" ], "interventions": [ { "name": "vorinostat", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "diagnostic laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 27, "start_date": "2010-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-05-03", "last_synced_at": "2026-05-22T07:47:03.315Z", "location_count": 7, "location_summary": "Chicago, Illinois • Ann Arbor, Michigan • Minneapolis, Minnesota + 4 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Portland", "state": "Oregon" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01076530" }, { "nct_id": "NCT00544284", "title": "Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Lymphoma", "Metastatic Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2005-01", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2013-02-15", "last_synced_at": "2026-05-22T07:47:03.315Z", "location_count": 2, "location_summary": "Duarte, California • Pasadena, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00544284" }, { "nct_id": "NCT05956821", "title": "Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma Multiforme", "Anaplastic Astrocytoma", "Fibrillary Astrocytomas", "Oligodendroglioma", "Diffuse Intrinsic Brainstem Glioma", "Diffuse Intrinsic Pontine Glioma", "DIPG Brain Tumor", "H3 K27M" ], "interventions": [ { "name": "SIACI of cetuximab and bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 20, "start_date": "2025-06-19", "completion_date": "2029-12-01", "has_results": false, "last_update_posted_date": "2025-12-08", "last_synced_at": "2026-05-22T07:47:03.315Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05956821" }, { "nct_id": "NCT02052648", "title": "Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma Multiforme", "Glioma", "Gliosarcoma", "Malignant Brain Tumor" ], "interventions": [ { "name": "Indoximod", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Stereotactic Radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "NewLink Genetics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 160, "start_date": "2014-03", "completion_date": "2019-06-20", "has_results": true, "last_update_posted_date": "2024-03-27", "last_synced_at": "2026-05-22T07:47:03.315Z", "location_count": 17, "location_summary": "Castro Valley, California • Los Angeles, California • Orange, California + 14 more", "locations": [ { "city": "Castro Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Athens", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02052648" }, { "nct_id": "NCT02800486", "title": "Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "Anaplastic Astrocytoma", "Anaplastic Oligoastrocytoma", "Glioma", "Brain Neoplasm", "Brain Cancer", "Brain Tumor", "Brain Tumor, Recurrent", "Brain Neoplasm, Malignant" ], "interventions": [ { "name": "Intra-arterial Cetuximab", "type": "DRUG" }, { "name": "Intra-arterial Mannitol", "type": "DRUG" }, { "name": "Hypofractionated re-irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2016-05", "completion_date": "2036-05", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-05-22T07:47:03.315Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02800486" } ] }